MX2009006170A - Compuestos y composiciones como inhibidores de cinasa. - Google Patents
Compuestos y composiciones como inhibidores de cinasa.Info
- Publication number
- MX2009006170A MX2009006170A MX2009006170A MX2009006170A MX2009006170A MX 2009006170 A MX2009006170 A MX 2009006170A MX 2009006170 A MX2009006170 A MX 2009006170A MX 2009006170 A MX2009006170 A MX 2009006170A MX 2009006170 A MX2009006170 A MX 2009006170A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- compositions
- kinase inhibitors
- trkc
- trkb
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Abstract
La invención proporciona una clase novedosa de compuestos, composiciones farmacéuticas que comprenden estos compuestos, y métodos para utilizar tales compuestos para tratar o prevenir enfermedades o los trastornos asociados con una actividad de cinasa anormal o mal regulada, en particular de TrkA, TrkB, TrkC, PDGFR y c-kit.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US86954806P | 2006-12-11 | 2006-12-11 | |
PCT/US2007/025447 WO2008073480A1 (en) | 2006-12-11 | 2007-12-11 | Compounds and compositions as kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2009006170A true MX2009006170A (es) | 2009-06-19 |
Family
ID=39132188
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2009006170A MX2009006170A (es) | 2006-12-11 | 2007-12-11 | Compuestos y composiciones como inhibidores de cinasa. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20100168182A1 (es) |
EP (1) | EP2102190A1 (es) |
JP (1) | JP2010512405A (es) |
KR (1) | KR20090092317A (es) |
CN (1) | CN101541788A (es) |
AU (1) | AU2007333536A1 (es) |
BR (1) | BRPI0720059A2 (es) |
CA (1) | CA2672101A1 (es) |
EA (1) | EA200900783A1 (es) |
MX (1) | MX2009006170A (es) |
WO (1) | WO2008073480A1 (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2947546B1 (fr) * | 2009-07-03 | 2011-07-01 | Sanofi Aventis | Derives de pyrazoles, leur preparation et leur application en therapeutique |
EP2838538B1 (en) | 2012-04-20 | 2017-03-15 | Annji Pharmaceutical Co., Ltd. | Cyclopropanecarboxylate esters of purine analogues |
CN102718659B (zh) * | 2012-06-27 | 2014-12-17 | 东南大学 | 一种4-溴-2-硝基苯乙酸的合成方法 |
WO2015039333A1 (en) * | 2013-09-22 | 2015-03-26 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF |
WO2015039334A1 (en) | 2013-09-22 | 2015-03-26 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF |
TWI672141B (zh) | 2014-02-20 | 2019-09-21 | 美商醫科泰生技 | 投予ros1突變癌細胞之分子 |
JP6744309B2 (ja) | 2014-12-02 | 2020-08-19 | イグニタ,インコーポレイテッド | 神経芽細胞腫の治療のための併用 |
CN105001167B (zh) * | 2015-07-16 | 2018-01-05 | 西安交通大学 | 1‑取代苯基‑3‑(4‑取代苯基氨基‑6‑喹唑啉基)脲类化合物及制备方法和用途 |
MX2018007266A (es) | 2015-12-18 | 2018-11-09 | Ignyta Inc | Combinaciones para el tratamiento del cancer. |
CN105669521B (zh) * | 2016-01-14 | 2019-01-15 | 成都知普莱生物医药科技有限公司 | 抗肿瘤化合物及其制备方法和应用 |
AU2018302170B2 (en) | 2017-07-19 | 2024-02-29 | Ignyta, Inc. | Pharmaceutical compositions comprising entrectinib |
JP7311498B2 (ja) | 2017-10-17 | 2023-07-19 | イグナイタ インコーポレイテッド | 薬学的組成物および剤形 |
CA3093445A1 (en) | 2018-03-08 | 2019-11-28 | Incyte Corporation | Aminopyrazine diol compounds as pi3k-.gamma. inhibitors |
US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2534921C (en) * | 2003-08-06 | 2011-06-14 | Vertex Pharmaceuticals Incorporated | Aminotriazole compounds useful as inhibitors of protein kinases |
CN1960988B (zh) * | 2004-06-10 | 2012-01-25 | Irm责任有限公司 | 作为蛋白激酶抑制剂的化合物和组合物 |
-
2007
- 2007-12-11 AU AU2007333536A patent/AU2007333536A1/en not_active Abandoned
- 2007-12-11 CN CNA2007800440673A patent/CN101541788A/zh active Pending
- 2007-12-11 MX MX2009006170A patent/MX2009006170A/es not_active Application Discontinuation
- 2007-12-11 JP JP2009541371A patent/JP2010512405A/ja active Pending
- 2007-12-11 CA CA002672101A patent/CA2672101A1/en not_active Abandoned
- 2007-12-11 WO PCT/US2007/025447 patent/WO2008073480A1/en active Application Filing
- 2007-12-11 EA EA200900783A patent/EA200900783A1/ru unknown
- 2007-12-11 US US12/518,831 patent/US20100168182A1/en not_active Abandoned
- 2007-12-11 EP EP07853354A patent/EP2102190A1/en not_active Withdrawn
- 2007-12-11 KR KR1020097014415A patent/KR20090092317A/ko not_active Application Discontinuation
- 2007-12-11 BR BRPI0720059-5A patent/BRPI0720059A2/pt not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
US20100168182A1 (en) | 2010-07-01 |
WO2008073480A1 (en) | 2008-06-19 |
EP2102190A1 (en) | 2009-09-23 |
AU2007333536A1 (en) | 2008-06-19 |
EA200900783A1 (ru) | 2009-12-30 |
JP2010512405A (ja) | 2010-04-22 |
BRPI0720059A2 (pt) | 2013-12-17 |
CN101541788A (zh) | 2009-09-23 |
CA2672101A1 (en) | 2008-06-19 |
KR20090092317A (ko) | 2009-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2009006170A (es) | Compuestos y composiciones como inhibidores de cinasa. | |
MX2009011951A (es) | Compuestos y composiciones como inhibidores de cinasa c-kit y pdgfr. | |
TN2012000081A1 (en) | Compounds and compositions as protein kinase inhibitors | |
TW200942537A (en) | Compounds and compositions as kinase inhibitors | |
MX2009004716A (es) | Compuestos y composiciones en la forma de inhibidores de quinasa de proteina. | |
MX2010009207A (es) | Compuestos y composiciones heterociclicos como inhibidores de c-kit y pdgfr cinasa. | |
MX2009007944A (es) | Compuestos y composiciones de purina como inhibidores de quinasa para el tratamiento de enfermedades relacionadas con plasmodium. | |
ATE544761T1 (de) | Pyrimidinderivate und zusammensetzungen als c-kit-und pdgfr-kinasehemmer | |
EA200901157A1 (ru) | Конденсированные кольцевые гетероциклические модуляторы киназы | |
TN2010000122A1 (en) | Compounds and compositions as modulators of gpr119 activity | |
MX2009009491A (es) | Compuestos y composiciones como moduladores de la actividad del gpr119. | |
EA200901032A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
HK1135103A1 (en) | Dihydropyridine derivatives useful as protein kinase inhibitors | |
WO2007106236A3 (en) | Pyrrolo-pyridine kinase modulators | |
ATE469151T1 (de) | Pyrrolopyridinderivate als proteinkinaseinhibitoren | |
MX2009011952A (es) | Compuestos y composiciones como inhibidores de cinasa c-kit y pdgfr. | |
MX2009006339A (es) | Compuestos y composiciones como inhibidores de actividad de receptor 1 de cannabinoide. | |
MX2009010207A (es) | Peptidos de hidrazido como inhibidores de proteasa ns3 de virus de hepatitis c. | |
WO2011014795A3 (en) | Compounds and compositions as syk kinase inhibitors | |
TNSN08373A1 (en) | Azolopyrimidines as inhibitors of cannabinoid 1 activity | |
ATE478863T1 (de) | Heterotetracyclische verbindungen als tpo- mimetica | |
MX2008013196A (es) | 5-amido-2-carboxiamida-indoles. | |
MX2008002166A (es) | Compuestos y composiciones como mimeticos de trombopoietina (tpo). | |
MX2010006206A (es) | Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina. | |
TW200740766A (en) | Substituted-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6-ligands |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HH | Correction or change in general | ||
FA | Abandonment or withdrawal |